Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ISCP
The International Society of Cardiovascular Pharmacotherapy was created to support and promote ethical, evidence-based, cardiovascular pharmacotherapy worldwide. ISCP represents an ideal forum for open discussions on all issues related to cardiovascular pharmacotherapy and the society endeavours to foster collaboration among health professionals around the World. ISCP promotes education, research… View more
Cardiovascular Effects of NSAIDs: A Review With a Focus on RA Patients
Author(s): Eirik Ikdahl , Anne Kerola , Eli Sollerud , et al Added: 1 year ago

Prevention & Chronic Conditions
AHA 25 Late-breaking Discussion: The VESALIUS-CV Trial
Author(s): Erin A Bohula , Harriette Van Spall Added: 2 months ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Erin A Bohula (Brigham & Women's Hospital, US) to discuss the primary results of the VESALIUS-CV trial, a large-scale, phase 3, double-blind, randomised, placebo-controlled study sponsored by Amgen.The VESALIUS-CV trial (NCT03872401) evaluated the impact of evolocumab, a PCSK9… View more

MI/ACS

Prevention & Chronic Conditions
Levosimendan in Cardiogenic Shock
Author(s): Hendri Susilo , Fan Maitri Aldian , Citrawati Dyah Kencono Wungu , et al Added: 1 year ago

MI/ACS
REDUCE-IT: CV Outcomes With Icosapent Ethyl by Baseline LDL-C
Author(s): Deepak L Bhatt Added: 10 months ago
In this insightful interview, Dr Deepak Bhatt (Mount Sinai Hospital, US) joins us to discuss findings from a post-hoc analysis of the REDUCE-IT trial, examining how icosapent ethyl affects cardiovascular outcomes across different baseline LDL-C levels.The study included 8,175 statin-treated patients with elevated cardiovascular risk and triglyceride levels between 135-499mg/dL. All participants… View more

Prevention & Chronic Conditions
Real-World Data for CV and Renal Outcomes in DKD
Author(s): David Wheeler Added: 7 months ago
ERA 2025 - Prof David Wheeler (University College London, London, UK) joins us to discuss outcomes from real-world data investigating cardiovascular and renal outcomes in patients with DKD.Interview Questions:1. How do real-world cardiovascular and renal outcomes compare to clinical trial results, and which data sources are giving us the best insights into DKD outcomes?2. What's the biggest gap… View more

Cardiovascular Renal Metabolic
Author(s): Billy A Caceres Added: 2 years ago
Dr Billy A Caceres (Columbia University School of Nursing, US), a renowned expert and lead author, recently discussed findings from the study titled "Differences in Ideal Cardiovascular Health Between Sexual Minority and Heterosexual Adults" published in JAMA Cardiology. The study aimed to determine whether there are disparities in cumulative cardiovascular health (CVH) scores between sexual… View more

Demographic
Ibrutinib, Venetoclax and Adverse Cardiovascular Events
Author(s): Roberta Esposito , Pierantonio Menna , Emanuela Salvatorelli , et al Added: 3 months ago

CV Disease in Special Populations

Prevention & Chronic Conditions
ESC 25 Guidelines Discussion: Management of Cardiovascular Disease and Pregnancy
Author(s): Harriette Van Spall , Julie De Backer Added: 4 months ago
ESC Congress 2025 - Late-breaker host Dr Harriette Van Spall (McMaster University, CA) joins Prof Julie De Backer (University Hospital Ghent, BE) to discuss the newly released 2025 ESC Guidelines for the Management of Cardiovascular Disease in Pregnancy. Together, they highlight key updates, critical advances in maternal cardiovascular care, and evidence-based recommendations tailored for this… View more

CV Disease in Special Populations

Guidelines & Statements